it’s time for highly bioavailable outpatient diuresis

Increasing fluid overload can impede the absorption of oral diuretics, compromising bioavailability.1-3 Through subcutaneous administration, FUROSCIX is able to deliver at-home, IV-equivalent diuresis with 99.6% absolute bioavailability—even in the presence of fluid overload.1* This allows you effective early intervention and your patients a return to maintenance diuretic therapy without ever leaving home.1

*

FUROSCIX is not for chronic use and should be replaced with oral diuretics as soon as practical.

In an open-label, crossover study

FUROSCIX AND IV FUROSEMIDE DEMONSTRATED EQUIVALENT BIOAVAILABILITY and diuresis1†

FUROSCIX Achieved 99.6% Absolute Bioavailability1

a graph depicting the bioavailability of furoscix over time

FUROSCIX reached Therapeutic plasma furosemide levels within 30 minutes1,4‡

In patients with reduced eGFR, furosemide plasma levels increased as renal function declined.

Mean Cmax values from FUROSCIX were lower than IV.4

FUROSCIX DEMONSTRATED EQUIVALENT DIURESIS TO IV1§

a graph comparing furoscix diuresis compared to IV furosemide diuresis

urine output was seen within 60 minutes with FUROSCIX4

Urine output between FUROSCIX and IV furosemide remained consistent regardless of eGFR.4

Urine sodium excretion for FUROSCIX1

286 mmol

0-8 H

341 mmol

0-24 H

Furosemide can cause dehydration and azotemia. If increasing azotemia and oliguria occur during treatment of severe progressive renal disease, furosemide should be discontinued.

Open-label, crossover study design1:

  • Study subjects represented likely FUROSCIX patients
    • NYHA Class II and Class III chronic heart failure
    • Fluid overload treated with oral diuretics for at least 3 months
  • Patients discontinued oral furosemide at least 24 hours prior to study treatment
  • Patients randomized to either drug, then received alternate treatment after 7-day wash out
  • The median (min-max) eGFR was 64 (41-98) mL/min/1.73 m2. 40% of patients were CKD Stage 2 and 53% were CKD Stage 3.4

†

90% confidence interval of 94.8-104.8. The design of the device used in this study was different from the current FUROSCIX On-Body Infusor, but it used the same administration profile.

‡

Based on mean ± SD 30-minute plasma concentration of 600 (± 209) ng/mL.1

§

Urine output over the periods of 0 to 8 hours and 0 to 24 hours following administration of 80-mg furosemide by 5-hour subcutaneous infusion with FUROSCIX, or IV administration of 2 doses of 40 mg 2 hours apart. Time 0 indicates the start of diuresis therapy.

Cmax=peak concentration; eGFR=estimated glomerular filtration rate; SD=standard deviation.